The burden of diabetes mellitus is still growing worldwide. With that, cardiovascular
diseases (CVD) remain the most life-threatening complications associated with diabetes.
Type 2 diabetes (T2D) patients are at 2 to 4 times higher risk of cardiovascular events
and death compared to the general population [
[1]
]. The main comorbidities linked with T2D are atherosclerosis, hyperglycemia, hypertension,
and dyslipidemia [
[2]
,
[3]
].To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to International Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Mortality and cardiovascular disease in type 1 and type 2 diabetes.N. Engl. J. Med. 2017; 376: 1407-1418https://doi.org/10.1056/NEJMoa1608664
- Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association.Circulation. 2020; 141: e779-e806https://doi.org/10.1161/CIR.0000000000000766
- Comprehensive Management of Cardiovascular Risk Factors for Adults With Type 2 Diabetes: A Scientific Statement From the American Heart Association.Circulation. 2022; 145: e722-e759https://doi.org/10.1161/CIR.0000000000001040
- Achievement of the ESC recommendations for secondary prevention of cardiovascular risk factors in high-risk patients with type 2 diabetes: a real-world national cohort analysis.Int. J. Cardiol. 2023; 377: 104-111https://doi.org/10.1016/j.ijcard.2023.02.004
- ESC/EAS Guidelines for the Management of Dyslipidaemias.Eur. Heart J. 2016; 37: 2999-3058https://doi.org/10.1093/eurheartj/ehw272
- ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS).Eur. Heart J. 2019; 41: 111-188https://doi.org/10.1093/eurheartj/ehz455
- ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force for diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and the European Association for the Study of Diabetes (EASD).Eur. Heart J. 2019; 41: 255-323https://doi.org/10.1093/eurheartj/ehz486
- Non-achievement of LDL-cholesterol targets in patients with diabetes at very-high cardiovascular risk receiving statin treatment: incidence and risk factors.Int. J. Cardiol. 2018; 268: 195-199https://doi.org/10.1016/j.ijcard.2018.04.068
- Influence of LDL-cholesterol lowering on cardiovascular outcomes in patients with diabetes mellitus undergoing coronary revascularization.J. Am. Coll. Cardiol. 2020; 76: 2197-2207https://doi.org/10.1016/j.jacc.2020.09.536
- Mechanistic insights regarding the role of SGLT2 inhibitors and GLP1 agonist drugs on cardiovascular disease in diabetes.Prog. Cardiovasc. Dis. 2019; 62: 349-357https://doi.org/10.1016/j.pcad.2019.07.005
Article info
Publication history
Published online: April 13, 2023
Accepted:
April 7,
2023
Received:
March 30,
2023
Identification
Copyright
© 2023 Elsevier B.V. All rights reserved.
